---

An evaluation of the 2019 novel coronavirus (COVID-19) disease

---

Editorial

Author Details : A.G. Nerkar*, Praneeta Pawale

Volume : 4, Issue : 3, Year : 2022

Article Page : 90-97

https://doi.org/10.18231/j.ctppc.2022.016

Suggest article by email

Get Permission

---

Abstract

WHO (World Health Organization) termed the diagnosed coronavirus as COVID-19. The pandemic outbreak of COVID-19 was manifested by intense acute respiratory system (SARS) and in Middle East known as Middle East Respiratory Syndrome (MERS). An outbreak of pneumonia of unknown aetiology in Wuhan City, Hubei province in China emerged in December of 2019. The virus originated in bats and became transmitted to people through but unknown middleman animals in Wuhan, China. There was not any clinically authorised antiviral drug to be had for use in opposition to COVID-19. However, few extensive-spectrum antiviral pills had been evaluated in opposition to COVID-19 in scientific trials, led to scientific recovery. In the cutting-edge evaluate, we summarize and relatively examine the worldwide emergence and pathogenicity of COVID-19 contamination.

Keywords: COVID­19, Corona virus, SARS, MERS, Pneumonia

How to cite : Nerkar A, Pawale P, An evaluation of the 2019 novel coronavirus (COVID-19) disease. Curr Trends Pharm Pharm Chem 2022;4(3):90-97

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.